Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …

Introduction: Daratumumab (DARA), a human, IgGκ monoclonal antibody targeting CD38, is
approved either as a single agent or in combination with anti-myeloma regimens for newly …

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical
activity in combination with bortezomib and dexamethasone versus bortezomib and …

In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of
disease progression or death by 63% and increased the overall response rate (ORR) versus …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Summary This United States community study evaluated the combination of daratumumab,
bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple …

Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …

Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …